Anxiety disorders are a prevalent and disabling condition. Because of high rates of treatment resistance, there is interest in new pharmacological treatment options such as second-generation antipsychotics. This systematic review evaluated the efficacy and tolerability of second-generation antipsychotics in the treatment of anxiety disorders. We found eleven randomised placebo-controlled trials, comparing quetiapine, olanzapine and risperidone with placebo and antidepressants. The vast majority of the available data was on quetiapine (> 3000 participants). Participants with generalised anxiety disorder responded significantly better to quetiapine than to placebo, measured as a reduction in the Hamilton Anxiety Scale (HAM-A). Participants treated with quetiapine were more likely to drop out due to adverse events, to gain weight, to suffer from sedation or to suffer from extrapyramidal side effects. The evidence on the other second-generation antipsychotics is currently too limited to draw any conclusions.
- Mental and physical health: re-assessing the relationship with employment propensity
- Exploratory Clinical Trials of Mind and Body Interventions for NCCAM High Priority Research Topics (R34)
- Inconsistencies in the roles of family- and paid- carers in monitoring health issues in people with learning disabilities: some implications for the integration of health and social care
- How moral are the principles of biomedical ethics? A cross-domain evaluation of the common morality hypothesis
- FDA approves new opioid pain reliever designed to be hard to abuse
Category Specific RSS